Total Payments
$202,498
2024 Payments
$13,650
Companies
68
Transactions
1,205
Medicare Patients
3,956
Medicare Billing
$514,054
Payment Breakdown by Category
Other$80,916 (40.0%)
Research$57,923 (28.6%)
Food & Beverage$32,886 (16.2%)
Consulting$21,643 (10.7%)
Travel$8,865 (4.4%)
Education$264.72 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $80,916 | 51 | 40.0% |
| Unspecified | $57,923 | 37 | 28.6% |
| Food and Beverage | $32,886 | 1,044 | 16.2% |
| Consulting Fee | $21,643 | 13 | 10.7% |
| Travel and Lodging | $8,865 | 39 | 4.4% |
| Education | $264.72 | 21 | 0.1% |
Payments by Type
General
$144,575
1,168 transactions
Research
$57,923
37 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Shire North American Group Inc | $63,544 | 73 | $0 (2019) |
| Ascendis Pharma Inc | $24,064 | 34 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $14,572 | 69 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $13,019 | 71 | $0 (2020) |
| ABBVIE INC. | $12,802 | 59 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $9,476 | 46 | $0 (2024) |
| Eli Lilly and Company | $8,782 | 3 | $0 (2024) |
| Novo Nordisk Inc | $8,354 | 95 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $7,049 | 6 | $0 (2022) |
| Lilly USA, LLC | $5,667 | 106 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $13,650 | 126 | Eli Lilly and Company ($6,777) |
| 2023 | $29,527 | 147 | Ascendis Pharma Inc ($22,758) |
| 2022 | $6,362 | 111 | Vertex Pharmaceuticals Incorporated ($1,200) |
| 2021 | $16,364 | 121 | Takeda Pharmaceuticals U.S.A., Inc. ($5,709) |
| 2020 | $5,822 | 124 | AbbVie Inc. ($1,446) |
| 2019 | $53,511 | 171 | Shire North American Group Inc ($35,414) |
| 2018 | $31,583 | 159 | Shire North American Group Inc ($20,606) |
| 2017 | $45,679 | 246 | Boehringer Ingelheim Pharmaceuticals, Inc. ($8,868) |
All Payment Transactions
1,205 individual payment records from CMS Open Payments — Page 1 of 49
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Ascendis Pharma Inc | — | Food and Beverage | In-kind items and services | $88.04 | General |
| 12/11/2024 | Kyowa Kirin, Inc. | Crysvita (Drug) | Food and Beverage | In-kind items and services | $15.85 | General |
| Category: fibroblast growth factor 23 (FGF23) blocking antibody. | ||||||
| 12/11/2024 | Mannkind Corporation | AFREZZA (Drug) | Food and Beverage | In-kind items and services | $9.92 | General |
| Category: DIABETES MEDICINE | ||||||
| 12/06/2024 | Medtronic, Inc. | MINIMED 780G (Device) | Food and Beverage | In-kind items and services | $29.17 | General |
| Category: Durable Pump | ||||||
| 12/03/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $24.98 | General |
| Category: DIABETES | ||||||
| 11/20/2024 | Xeris Pharmaceuticals, Inc. | RECORLEV (Drug) | Food and Beverage | In-kind items and services | $17.70 | General |
| Category: Adrenal steroidogenesis inhibitor | ||||||
| 11/20/2024 | Xeris Pharmaceuticals, Inc. | RECORLEV (Drug) | Food and Beverage | In-kind items and services | $4.22 | General |
| Category: Adrenal steroidogenesis inhibitor | ||||||
| 11/19/2024 | Novo Nordisk Inc | Sogroya (Biological) | Food and Beverage | In-kind items and services | $6.72 | General |
| Category: Growth Hormone | ||||||
| 11/18/2024 | Mannkind Corporation | AFREZZA (Drug) | Food and Beverage | In-kind items and services | $3.98 | General |
| Category: DIABETES MEDICINE | ||||||
| 11/11/2024 | Ascendis Pharma Inc | — | Food and Beverage | In-kind items and services | $83.92 | General |
| 11/08/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $133.60 | General |
| Category: Cardio-renal | ||||||
| 11/08/2024 | Medtronic, Inc. | MINIMED 780G (Device) | Food and Beverage | In-kind items and services | $23.89 | General |
| Category: Durable Pump | ||||||
| 11/06/2024 | Alexion Pharmaceuticals, Inc. | STRENSIQ (Biological) | Food and Beverage | In-kind items and services | $17.47 | General |
| Category: Rare Disease | ||||||
| 11/05/2024 | Xeris Pharmaceuticals, Inc. | RECORLEV (Drug) | Food and Beverage | In-kind items and services | $74.44 | General |
| Category: Adrenal steroidogenesis inhibitor | ||||||
| 11/05/2024 | Amgen Inc. | TEPEZZA (Biological) | Food and Beverage | In-kind items and services | $24.58 | General |
| Category: Inflammation/Rare Disease | ||||||
| 10/17/2024 | Mannkind Corporation | AFREZZA (Drug) | Food and Beverage | In-kind items and services | $25.29 | General |
| Category: DIABETES MEDICINE | ||||||
| 10/16/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $33.07 | General |
| Category: Inflammation/Rare Disease | ||||||
| 10/15/2024 | Lexicon Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $89.25 | General |
| 10/10/2024 | Chiesi USA, Inc. | MYCAPSSA (Drug) | Food and Beverage | Cash or cash equivalent | $21.06 | General |
| Category: ACROMEGALY | ||||||
| 10/10/2024 | Chiesi USA, Inc. | MYCAPSSA (Drug) | Food and Beverage | Cash or cash equivalent | $3.24 | General |
| Category: ACROMEGALY | ||||||
| 10/04/2024 | Medtronic, Inc. | MINIMED 780G (Device) | Food and Beverage | In-kind items and services | $36.39 | General |
| Category: Durable Pump | ||||||
| 10/03/2024 | Chiesi USA, Inc. | MYALEPT (Drug) | Food and Beverage | Cash or cash equivalent | $148.15 | General |
| Category: GENERALIZED LIPODYSTROPHY | ||||||
| 10/03/2024 | Alexion Pharmaceuticals, Inc. | STRENSIQ (Biological) | Food and Beverage | In-kind items and services | $22.97 | General |
| Category: Rare Disease | ||||||
| 09/26/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $115.92 | General |
| 09/26/2024 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $27.43 | General |
| Category: Bone Health | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| AN OPEN-LABEL STUDY INVESTIGATING THE SAFETY AND EFFICACY OF RHPTH1-84 IN SUBJECTS WITH HYPOPARATHYROIDISM | Shire North American Group Inc | $26,410 | 9 |
| A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) | Eli Lilly and Company | $8,782 | 3 |
| Toujeo Real World Insulin Nai | SANOFI-AVENTIS U.S. LLC | $7,474 | 4 |
| AN OPEN-LABEL STUDY INVESTIGATING THE SAFETY AND EFFICACY OF RHPTH(1-84) IN SUBJECTS WITH HYPOPARATHYROIDISM | Takeda Pharmaceuticals U.S.A., Inc. | $6,918 | 4 |
| An Open-label Study Investigating the Safety and Efficacy of rhPTH1-84 in Subjects With Hypoparathyroidism | Shire North American Group Inc | $5,200 | 3 |
| A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism | ABBVIE INC. | $2,983 | 13 |
| Corcept Study Awareness | Corcept Therapeutics | $156.24 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 812 | 1,710 | $373,105 | $117,866 |
| 2022 | 9 | 809 | 1,613 | $343,281 | $107,416 |
| 2021 | 7 | 924 | 2,088 | $326,280 | $134,442 |
| 2020 | 15 | 1,411 | 2,632 | $387,385 | $154,329 |
Total Patients
3,956
Total Services
8,043
Medicare Billing
$514,054
Procedure Codes
40
All Medicare Procedures & Services
40 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 225 | 577 | $161,560 | $54,110 | 33.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 299 | 701 | $147,210 | $44,339 | 30.1% |
| 76536 | Ultrasound scan of head and neck soft tissue | Office | 2023 | 61 | 67 | $23,450 | $5,787 | 24.7% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2023 | 57 | 159 | $11,925 | $4,044 | 33.9% |
| 93923 | Complete ultrasound study of arm and leg arteries | Office | 2023 | 34 | 34 | $8,500 | $3,373 | 39.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 18 | 19 | $6,650 | $2,539 | 38.2% |
| 95250 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with provider supplied equipment | Office | 2023 | 14 | 16 | $5,280 | $1,796 | 34.0% |
| 83036 | Hemoglobin a1c level | Office | 2023 | 69 | 102 | $5,100 | $945.75 | 18.5% |
| 95905 | Nerve conduction study of arm or leg movement and/or feeling with review and report | Office | 2023 | 35 | 35 | $3,430 | $932.28 | 27.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 199 | 487 | $136,360 | $46,282 | 33.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 292 | 663 | $139,230 | $41,345 | 29.7% |
| 76536 | Ultrasound scan of head and neck soft tissue | Office | 2022 | 76 | 84 | $29,400 | $7,090 | 24.1% |
| 93923 | Complete ultrasound study of arm and leg arteries | Office | 2022 | 39 | 39 | $9,750 | $4,120 | 42.3% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2022 | 45 | 121 | $9,075 | $3,154 | 34.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 14 | 15 | $5,250 | $1,924 | 36.7% |
| 83036 | Hemoglobin a1c level | Office | 2022 | 95 | 153 | $7,650 | $1,418 | 18.5% |
| 95905 | Nerve conduction study of arm or leg movement and/or feeling with review and report | Office | 2022 | 37 | 37 | $3,626 | $1,141 | 31.5% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 12 | 14 | $2,940 | $942.16 | 32.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 268 | 757 | $164,380 | $73,655 | 44.8% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 286 | 610 | $93,828 | $39,249 | 41.8% |
| 76536 | Ultrasound of head and neck | Office | 2021 | 70 | 74 | $19,900 | $6,951 | 34.9% |
| 95251 | Ambulatory continuous glucose (sugar) including interpretation and report for a minimum of 72 hours | Office | 2021 | 68 | 202 | $15,150 | $5,458 | 36.0% |
| 83036 | Hemoglobin a1c level | Office | 2021 | 162 | 357 | $17,850 | $3,384 | 19.0% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2021 | 45 | 57 | $8,442 | $3,143 | 37.2% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2021 | 25 | 31 | $6,730 | $2,603 | 38.7% |
About Dr. Lisa Abbott, MD
Dr. Lisa Abbott, MD is a Endocrinology, Diabetes & Metabolism healthcare provider based in Reno, Nevada. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/02/2006. The National Provider Identifier (NPI) number assigned to this provider is 1609883701.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Lisa Abbott, MD has received a total of $202,498 in payments from pharmaceutical and medical device companies, with $13,650 received in 2024. These payments were reported across 1,205 transactions from 68 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($80,916).
As a Medicare-enrolled provider, Abbott has provided services to 3,956 Medicare beneficiaries, totaling 8,043 services with total Medicare billing of $514,054. Data is available for 4 years (2020–2023), covering 40 distinct procedure/service records.
Ad
Practice Information
- Specialty Endocrinology, Diabetes & Metabolism
- Other Specialties Diabetes & Metabolism
- Location Reno, NV
- Active Since 08/02/2006
- Last Updated 12/13/2019
- Taxonomy Code 207RE0101X
- Entity Type Individual
- NPI Number 1609883701
Products in Payments
- NATPARA (PARATHYROID HORMONE) (Drug) $42,463
- NATPARA (Drug) $28,130
- INVOKANA (Drug) $13,096
- JARDIANCE (Drug) $12,922
- TOUJEO (Drug) $8,073
- Synthroid (Drug) $6,526
- Victoza (Drug) $5,966
- SOLIQUA (Drug) $5,732
- Korlym (Drug) $5,473
- JATENZO (Drug) $4,635
- FARXIGA (Drug) $3,315
- SYNTHROID (Drug) $3,273
- ARMOUR THYROID (Drug) $2,897
- DISEASE STATE (Drug) $2,436
- Eversense (Device) $2,170
- SKYTROFA (Drug) $1,917
- AFREZZA (Drug) $1,489
- Vascepa (Drug) $1,180
- TEPEZZA (Drug) $1,034
- EVENITY (Biological) $887.92
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Endocrinology, Diabetes & Metabolism Doctors in Reno
Dr. Nitesh Kuhadiya, M.d; Mph, M.D; MPH
Endocrinology, Diabetes & Metabolism — Payments: $1.1M
Endocrinology, Diabetes & Metabolism $1.1M
Dr. Claude Lardinois, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $331,124
Endocrinology, Diabetes & Metabolism $331,124
Michael Raymund Gonzales, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $80,625
Endocrinology, Diabetes & Metabolism $80,625
Daniel Caruso, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $52,235
Endocrinology, Diabetes & Metabolism $52,235
David Howard, M.d., Ph.d, M.D., PH.D
Endocrinology, Diabetes & Metabolism — Payments: $15,691
Endocrinology, Diabetes & Metabolism $15,691
Robert Fredericks, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $11,315
Endocrinology, Diabetes & Metabolism $11,315